{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:16:41Z","timestamp":1781839001790,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ijrobp.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T03:25:08Z","timestamp":1550028308000},"page":"1038-1044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-9906","authenticated-orcid":false,"given":"Zaid A.","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro A.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Limbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.02.010_bib1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ijrobp.2010.10.015","article-title":"High-dose-rate monotherapy: Safe and effective brachytherapy for patients with localized prostate cancer","volume":"81","author":"Demanes","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-dose-rate monotherapy for localized prostate cancer: 10-year results","volume":"94","author":"Hauswald","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2017.09.038","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer","volume":"126","author":"Strouthos","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ijrobp.2016.12.013","article-title":"Nationwide, multicenter, retrospective study on high-dose-rate brachytherapy as monotherapy for prostate cancer","volume":"97","author":"Yoshioka","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","article-title":"Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer","volume":"94","author":"Jawad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijrobp.2019.02.010_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable preliminary outcomes for men with low-and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"International Journal of Radiation Oncology* Biology* Physics"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2017.01.025","article-title":"Increasing fractional doses increases the probability of benign PSA bounce in patients undergoing definitive HDR brachytherapy for prostate cancer","volume":"98","author":"Hauck","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.brachy.2013.11.007","article-title":"ACR appropriateness criteria high-dose-rate brachytherapy for prostate cancer","volume":"13","author":"Hsu","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American brachytherapy society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib12","unstructured":"NCCN. NCCN guidelines: Prostate cancer (4.2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed October 20, 2018."},{"key":"10.1016\/j.ijrobp.2019.02.010_bib13","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1016\/j.ijrobp.2018.02.107","article-title":"P19) single fraction high dose rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early results of a single institutional experience","volume":"101","author":"Barnes","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.radonc.2017.10.039","article-title":"Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial","volume":"126","author":"Gomez-Iturriaga","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib18","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.brachy.2017.04.018","article-title":"Prostate HDR monotherapy: Initial efficacy results from a randomized trial of one versus two fractions","volume":"16","author":"Morton","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.brachy.2017.10.001","article-title":"Pattern of relapse and dose received by the recurrent intraprostatic nodule in low-to intermediate-risk prostate cancer treated with single fraction 19 gy high-dose-rate brachytherapy","volume":"17","author":"Mendez","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.brachy.2018.06.002","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results","volume":"17","author":"Prada","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2307\/3574407","article-title":"The effect of multiple small doses of X rays on skin reactions in the mouse and a basic interpretation","volume":"66","author":"Douglas","year":"1976","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2019.02.010_bib22","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.brachy.2017.04.038","article-title":"HDR monotherapy in prostate cancer: Radiobiological considerations when determining biologically effective dose in clinical trials","volume":"16","author":"Tien","year":"2017","journal-title":"Brachyther"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619302056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619302056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T21:45:06Z","timestamp":1563486306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619302056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0360301619302056"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.010","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}